Bile acids and incretins as modulators of obesity-associated atherosclerosis [PDF]
Frontiers in Cardiovascular MedicineObesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic ...
Andrijana Kirsch +4 more
doaj +5 more sources
Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease [PDF]
Pharmaceutics, 2023 Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2 diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated to play a markedly protective role for the cardiovascular system beyond ...
Gian Paolo Ussia +2 more
exaly +4 more sources
Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis [PDF]
Endokrynologia Polska, 2021 INTRODUCTION: The effect of incretins including dipeptidyl peptidase 4 inhibitors (DPP4-Is) and glucagon-like peptide1 receptor agonists (GLP1-ras) in the treatment of type 2 diabetes increasing the risk of fracture remains controversial.
Qing-xin Kong +5 more
doaj +3 more sources
Pleiotropic effects of incretins [PDF]
Indian Journal of Endocrinology and Metabolism, 2012 Drugs that augment the incretin system [glucagon like peptide (GLP) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] represent a novel class of anti-hyperglycemic agents that have shown to improve the health and survival of beta-cells (improvement
Vishal Gupta
doaj +2 more sources
12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus [PDF]
Clinical Pharmacology: Advances and Applications, 2018 Simone Perna,1 Manuela Mainardi,2 Paolo Astrone,2 Carlotta Gozzer,3 Anna Biava,1 Ruben Bacchio,3 Daniele Spadaccini,3 Sebastiano Bruno Solerte,2 Mariangela Rondanelli4 1Department of Biology, College of Science, University of Bahrain, Sakhir Campus ...
Perna S +8 more
doaj +6 more sources
Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection [PDF]
Frontiers in MedicineEndothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Allegra Battistoni +5 more
doaj +2 more sources
Physiological Reports, 2019 Bariatric surgery is now the most widely used intervention for the treatment of human obesity. A large body of literature has demonstrated its efficacy in sustained weight loss and improvement in its associated comorbidities.
Matthew Brady +2 more
exaly +2 more sources
Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
Health Sciences Review, 2023 Diabetes mellitus and osteoporosis are chronic illnesses associated with adverse health outcomes. Studies have reported common linkages between energy and bone metabolism.
Faraha Ahmed +8 more
doaj +1 more source
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020 [PDF]
Endocrinology and Metabolism, 2021 Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives.
Eun-Jung Rhee +2 more
doaj +1 more source
Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
Medicina, 2022 The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and ...
Angelo Maria Patti +10 more
doaj +1 more source